Merit Medical Systems, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US5898891040
USD
84.09
-0.3 (-0.36%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Merit Medical Systems, Inc. stock-summary
stock-summary
Merit Medical Systems, Inc.
Pharmaceuticals & Biotechnology
Merit Medical Systems, Inc. is a manufacturer and marketer of disposable medical devices used in a range of interventional, diagnostic and therapeutic medical procedures. The Company operates in two segments: cardiovascular and endoscopy. The cardiovascular segment consists of cardiology and radiology devices, which assist in diagnosing and treating coronary arterial disease, peripheral vascular disease and other non-vascular diseases, and includes embolotherapeutic, cardiac rhythm management (CRM), electrophysiology (EP), and interventional oncology and spine devices. Its endoscopy segment consists of gastroenterology and pulmonology medical devices, which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors. Within its segments, the Company offers products focused in four product groups: peripheral intervention, cardiac intervention, interventional oncology and spine, and endoscopy.
Company Coordinates stock-summary
Company Details
1600 W Merit Pkwy , SOUTH JORDAN UT : 84095-2416
stock-summary
Tel: 1 801 25316001 801 2084167
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 115 Schemes (57.2%)

Foreign Institutions

Held by 150 Foreign Institutions (11.58%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Fred Lampropoulos
Chairman of the Board, President, Chief Executive Officer
Ms. Lynne Ward
Director
Mr. A. Scott Anderson
Independent Director
Ms. Jill Anderson
Independent Director
Mr. Thomas Gunderson
Independent Director
Dr. F. Ann Millner
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
382 Million
(Quarterly Results - Jun 2025)
Net Profit:
33 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 5,468 Million (Small Cap)

stock-summary
P/E

42.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.27

stock-summary
Return on Equity

8.65%

stock-summary
Price to Book

3.67